An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC (ACTRN12624001373561)
ADOPT-LUNG ETOP 25-23
This trial is No longer recruiting
Registration number ACTRN12624001373561
Program & service
This trial is being run with the Cancer service, and as part of the Medical Oncology program.
Trial phase
Phase 3
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Dr Maggie Moore
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR